In the new issue of IAVI Report we wrote about how researchers at the AIDS Vaccine 2010 conference in Atlanta discussed the limited
window of opportunity for conducting clinical trials to
test partially effective
HIV prevention strategies, including
HIV vaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combination.